CalciMedica Closes Second Tranche of $12M Series C Financing

CalciMedica, a La Jolla, California-based biotechnology company dedicated to the discovery and development of novel small molecule drugs for the treatment of autoimmune and inflammatory diseases, announced the closing of the second tranche of its $12m Series C financing.

The round is led by BiogenIdec New Ventures, with participation from Sanderling Ventures and SR One.

To date, the company has raised a total of $19m in equity funding. After closing a seed financing from SR One in December 2006 and a Series B round led by Sanderling Ventures, with participation from SR One, in August 2007, CalciMedica received the first tranche of the curent Series C funding in November 2008.

As stated by Gonul Velicelebi, Ph.D., Founder, President and Chief Executive Officer of the company, during the last year, CalciMedica has made significant progress in identifying and characterizing selective calcium release-activated calcium (CRAC) channel inhibitors with attractive pharmaceutical properties that have the potential to become safe and effective drugs to treat inflammatory and autoimmune diseases. 



Join the discussion